August 28, 2026 BetterLife Pharma Inc. Announces Pricing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
August 24, 2026 BetterLife Pharma Inc. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
July 13, 2026 BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism
July 9, 2026 BetterLife Pharma Announces Appointment of John W. LaRocca to Board of Directors and Audit Committee
July 6, 2026 BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1
June 25, 2026 BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1
June 22, 2026 BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing
June 15, 2026 BetterLife Pharma Announces Intent to Complete CAD $2 Million in Convertible Debenture to Complete BETR-001 IND Filing
